Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01032915 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

125

Enrollment

INDUSTRY

Sponsor class

Stopped Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint

Conditions

Non-infectious Uveitis

Interventions

BIOLOGICAL: AIN457
BIOLOGICAL: AIN457
BIOLOGICAL: AIN457
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals